Page 7 of 15 · 360 questions tagged semaglutide.
I would like to know how much of this is established and how much is a reasonable story. I would like the mechanism, because I want to be able to reason about the…
Two COAs for the same nominal product give me endotoxin specifications of "less than 10 EU/mg" and "less than 0.5 EU/mg" respectively. Both pass. The second vendor…
Numbers first: STEP 4 · orforglipron. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists…
Numbers first: SURMOUNT-OSA · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
What I have: ESSENCE · retatrutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the evidence exists and…
I have looked for a randomised comparison of dosing frequency within a single molecule in this class and cannot find one. Every phase 3 trial I can find fixed the…
I have the full paper rather than the abstract, and the supplementary appendix. I understand the observation; what I do not understand is the mechanism behind it. I…
A report I have includes traces at two wavelengths from the same injection, using a diode-array detector. The 214 nm trace integrates to 98.6% and the 280 nm trace to…
Setup, so nobody has to ask: STEP 5 · mazdutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
The specifics, since they change the answer: STEP 2 · survodutide. Somebody stated this to me confidently and I would like to check it before repeating it. I would…
I have been quoted roughly four times the price of a purity-plus-identity panel for something described as "tryptic digest with LC-MS/MS peptide mapping and sequence…
The particulars: PIONEER-4 · semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
The specifics, since they change the answer: REDEFINE-1 · survodutide. I want to understand what this actually establishes, as opposed to what it is being used to…
Concretely: SOUL · liraglutide. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone points me at one. Is there data…
My weekly dose currently lands on a Thursday and that is now the worst day of my week for it. I want it on a Sunday. That is a three-day move and I can see two ways…
I have the full paper rather than the abstract, and the supplementary appendix. I would like the mechanism, because I want to be able to reason about the cases nobody…
Conditions: STEP 4 · tirzepatide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…
Setup, so nobody has to ask: SURPASS-3 · cagrilintide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
This matters because it predicts what a related molecule should do. This is one of those things that everyone repeats and nobody derives. This matters practically,…
FLOW tested semaglutide 1.0 mg in people with type 2 diabetes and chronic kidney disease, and reported a hazard ratio of 0.76 for its composite kidney endpoint. I…
I noticed that the placebo arms in this literature do not behave consistently. STEP 1 placebo loses 2.4%. STEP 3 placebo loses 5.7%. SURMOUNT-3 placebo gains 2.5%.…
The case in front of me: semaglutide · semaglutide. I would like the axes of comparison first and the recommendation second. I have tried the first option and it…
Setup, so nobody has to ask: SURMOUNT-OSA · a GLP-1 receptor agonist. I have read the primary source rather than the summary, which has left me with more questions. I…
Concretely: SURMOUNT-4 · oral semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…